These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 38590427)

  • 1. Nanomedicines against Chagas disease: a critical review.
    Morilla MJ; Ghosal K; Romero EL
    Beilstein J Nanotechnol; 2024; 15():333-349. PubMed ID: 38590427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomedicines against Chagas disease: an update on therapeutics, prophylaxis and diagnosis.
    Morilla MJ; Romero EL
    Nanomedicine (Lond); 2015 Feb; 10(3):465-81. PubMed ID: 25707979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection.
    Barbosa JMC; Pedra Rezende Y; de Melo TG; de Oliveira G; Cascabulho CM; Pereira ENGDS; Daliry A; Salem KS
    Microbiol Spectr; 2022 Feb; 10(1):e0185221. PubMed ID: 35138142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current trends in the pharmacological management of Chagas disease.
    Ribeiro V; Dias N; Paiva T; Hagström-Bex L; Nitz N; Pratesi R; Hecht M
    Int J Parasitol Drugs Drug Resist; 2020 Apr; 12():7-17. PubMed ID: 31862616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease.
    Rolon M; Hanna E; Vega C; Coronel C; Dea-Ayuela MA; Serrano DR; Lalatsa A
    Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Approaches for the Treatment of Chagas Disease.
    Pandey RP; Nascimento MS; Moore CE; Raj VS; Kalil J; Cunha-Neto E
    Curr Drug Targets; 2021; 22(7):835-841. PubMed ID: 33238855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benznidazole Nanoformulates: A Chance to Improve Therapeutics for Chagas Disease.
    Vinuesa T; Herráez R; Oliver L; Elizondo E; Acarregui A; Esquisabel A; Pedraz JL; Ventosa N; Veciana J; Viñas M
    Am J Trop Med Hyg; 2017 Nov; 97(5):1469-1476. PubMed ID: 29016287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole.
    Ferraz LRM; Alves AÉG; Nascimento DDSDS; Amariz IAE; Ferreira AS; Costa SPM; Rolim LA; Lima ÁAN; Rolim Neto PJ
    Acta Trop; 2018 Sep; 185():127-132. PubMed ID: 29452113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
    Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A quinoxaline derivative as a potent chemotherapeutic agent, alone or in combination with benznidazole, against Trypanosoma cruzi.
    Rodrigues JH; Ueda-Nakamura T; Corrêa AG; Sangi DP; Nakamura CV
    PLoS One; 2014; 9(1):e85706. PubMed ID: 24465654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening of Potential anti-Trypanosoma cruzi Candidates: In Vitro and In Vivo Studies.
    Soeiro Mde N; de Castro SL
    Open Med Chem J; 2011; 5():21-30. PubMed ID: 21629508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fexinidazole: a potential new drug candidate for Chagas disease.
    Bahia MT; de Andrade IM; Martins TA; do Nascimento ÁF; Diniz Lde F; Caldas IS; Talvani A; Trunz BB; Torreele E; Ribeiro I
    PLoS Negl Trop Dis; 2012; 6(11):e1870. PubMed ID: 23133682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benznidazole and amiodarone combined treatment attenuates cytoskeletal damage in
    Barbosa JMC; Pedra-Rezende Y; Pereira LD; de Melo TG; Barbosa HS; Lannes-Vieira J; de Castro SL; Daliry A; Salomão K
    Front Cell Infect Microbiol; 2022; 12():975931. PubMed ID: 36093188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of Benznidazole in Experimental Chronic Chagas Disease Using the Swiss Mouse-Berenice-78 Trypanosoma cruzi Strain Model.
    de Jesus SM; Pinto L; Moreira FL; Nardotto GHB; Cristofoletti R; Perin L; Fonseca KDS; Barbêdo P; Bandeira LC; Vieira PMA; Carneiro CM
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.
    Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A
    Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of Patients for Whom Benznidazole Was Released Through the CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2011-2018.
    Herwaldt BL; Dougherty CP; Allen CK; Jolly JP; Brown MN; Yu P; Yu Y
    MMWR Morb Mortal Wkly Rep; 2018 Jul; 67(29):803-805. PubMed ID: 30048425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and pharmacological profile of benznidazole for treatment of Chagas disease.
    Kratz JM; Garcia Bournissen F; Forsyth CJ; Sosa-Estani S
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):943-957. PubMed ID: 30111183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanotechnology: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(19):1-43. PubMed ID: 23074489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi.
    Puente V; Demaria A; Frank FM; Batlle A; Lombardo ME
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006764. PubMed ID: 30240395
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.